Childhood Acute Lymphoblastic LeukemiaChildren's health
What this study is
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
What's being tested
- Non-Interventional Study
Intervention · OTHER
Non-interventional study
Study details
- Sponsor
- Mayo Clinic
- Conditions
- Childhood Acute Lymphoblastic Leukemia · Childhood Lymphoblastic Lymphoma
- Enrolling
- 15 people
- Starts
- 2025-07-31
- Est. completion
- 2026-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 2 Years – 22 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age 2-21.5 years
- Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
- Planned treatment with Cal-PEG
- Informed consent obtained from parents or guardians
You can't join if
- Pre-existing coagulation disorders
- Known hypersensitivity to asparaginase products
- Liver failure
- Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
- Currently pregnant
- Use of systemic blood thinner within 48 hours prior to study blood draw
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openMayo Clinic in Rochester
Rochester, Minnesota, United States
- Clinical Trials · Contactmayocliniccancerstudies@mayo.edu
- Madeleine B. O'Keefe, MD · Principal investigator
Recruiting
Study team
Sponsor
Mayo Clinic
Study ID 24-012104
Principal investigator
Madeleine B. O'Keefe, MD
Mayo Clinic in Rochester
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.